NetworkNewsAudio News

InvestorBrandNetwork-NetworkNewsAudio News-CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces FDA Filing of IND for its Brain Cancer Drug Berubicin

Season 1, Episode 37 | 2020 | 5:05 | FINANCE |

CNS Pharmaceuticals (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has submitted an Investigational New Drug (“IND”) application, which has been accepted for review, to the U.S. Food and Drug Administration (“FDA”) for Berubicin in the treatment of Glioblastoma Multiforme (“GBM”). The Company plans to evaluate the efficacy of Berubicin in a Phase 2 Trial for adults with GBM who have failed first-line therapy and commence the trial within the first quarter of 2021, pending the FDA’s acceptance of the Company’s filing.

Up next

More Episodes


Commenting is only available to members. Sign In